Liane König

O-(2-[18F]fluoroethyl)-L-tyrosine-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent glioblastoma (GLIAA/NOA-10 ARO2013-01): a multicentre, open-label, randomised trial

Anca‐Ligia Grosu, Wolfgang Weber, Erika Graf, Michael D. Mix et autres

BACKGROUND: F]fluoroethyl)-L-tyrosine (FET)-PET has a higher specificity than contrast-enhanced T1-weighted MRI (CE-T1MRI) in diagnosing recurrent glioblastoma. We aimed to evaluate whether a FET-PET-based target volume delineation, compared with CE-T1MRI, improves outcomes in patients with recurrent glioblastoma scheduled for re-irradiation. METHODS: GLIAA was …

de, ch (code pays fourni par la source)

2401 Oncological outcome of re-irradiation for recurrent glioblastoma – Results of a prospective multicenter trial (GLIAA, NCT01252459)

Ilinca Popp, Wolfgang Weber, Erika Graf, Michael D. Mix et autres

Re-irradiation in recurrent glioblastoma: PET- or MRI-based? Results of a prospective randomized clinical trial.

Ilinca Popp, Wolfgang Weber, Erika Graf, Michael D. Mix et autres

2021 Background: Re-irradiation is an important treatment option for recurrent glioblastoma (rGBM). Here, we aimed to compare the oncological outcome of a re-irradiation target volume delineation based on O-(2-[18F]fluoroethyl)-L-tyrosine (FET) positron emission tomography (PET) with the one of a treatment based on …

de (code pays fourni par la source)

1915: PET vs. MRI based reirradiation in glioblastoma. A prospective randomized trial (GLIAA, NCT01252459)

Anca‐Ligia Grosu, Wolfgang Weber, Erika Graf, Michael D. Mix et autres

Hydrogel injection reduces rectal toxicity after radiotherapy for localized prostate cancer

Michael Pinkawa, Vanessa Berneking, Liane König, Dilini Frank et autres

de (code pays fourni par la source)